Paper Details

  1. Home
  2. Paper Details

A Systemic Lupus Erythematosus Patient with Cutaneous <i>Mycobacterium haemophilum</i> Infection under Belimumab Treatment: A Case Report.

Author: AonoAkio, FukuiYukiko, HasegawaToshio, IkedaShigaku, KimJonghun, MitaraiSatoshi, NakamuraAyako, TadaKurisu, TakeiSatomi, UeharaYuki

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Belimumab is a B cell-targeted biologic drug used to treat systemic lupus erythematosus (SLE). This case report describes a patient who developed Mycobacterium haemophilum infection after starting belimumab therapy. This suggests that belimumab may increase the risk of mycobacterial infections.
Paper Details　
Original Abstract of the Article :
A 38-year-old female with systemic lupus erythematosus (SLE) initiated belimumab treatment. One month later, she presented with a reddish painful swelling on her right lower leg. She was treated with ceftriaxone and vancomycin. However, novel erythematous papules and indurated nodules appeared on bo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608360/

データ提供：米国国立医学図書館（NLM）

SLE and Mycobacterial Infections: A Case of Cutaneous Mycobacterium haemophilum Infection

Systemic lupus erythematosus (SLE), a chronic autoimmune disease, often requires treatment with biologic therapies to manage its symptoms. This case report highlights a potential complication associated with belimumab, a commonly used biologic therapy for SLE. The report describes a case of a patient with SLE who developed a cutaneous infection with Mycobacterium haemophilum while receiving belimumab treatment.

Belimumab and Mycobacterial Infections: A Potential Risk for SLE Patients

This case report suggests a possible association between belimumab treatment and the development of mycobacterial infections in SLE patients. The report emphasizes the importance of vigilant monitoring for mycobacterial infections in patients receiving belimumab therapy, particularly those with underlying risk factors.

Navigating the Risks and Benefits of Biologic Therapies for SLE

This case report highlights the complexities of managing SLE with biologic therapies. While belimumab offers significant benefits in managing SLE, the risk of developing mycobacterial infections must be carefully considered. The report underscores the need for a balanced approach to treatment, weighing the potential benefits against the potential risks.

Dr.Camel's Conclusion

This case report serves as a reminder of the potential risks associated with biologic therapies for SLE. The development of mycobacterial infections, while uncommon, underscores the importance of careful monitoring and early intervention in patients receiving belimumab treatment. This report highlights the ongoing need for further research to fully understand the potential complications associated with biologic therapies for SLE and develop strategies to mitigate these risks.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-10-29
Further Info :

Pubmed ID

37853868

DOI: Digital Object Identifier

PMC10608360

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.